Wnts are secreted lipid-modified glycoproteins that regulate cell proliferation, cell polarity, and cell fate determination through a range of pathways.
Notes
containing protein (β-TrCP), a subunit of the E3 ubiquitin ligase complex, leading to ubquitin-dependent proteolysis. 13, 14 In the present study, cell-based chemical screening with two reporter cell lines (HEK293-TOPFlash and HEK293-RL) was used to identify antimycin A, an inhibitor of complex III in the mitochondrial respiratory chain, as an antagonist of the Wnt/β-catenin pathway. Antimycin A suppressed β-catenin response transcription (CRT), which had been stimulated by Wnt3a-conditioned medium (Wnt3a-CM), and down-regulated the level of intracellular β-catenin. In contrast, 2-methoxyantimycin A3, an inactive analogue of antimycin A that does not inhibit mitochondrial electron transport chain, did not inhibit Wnt3a-CM-induced CRT or decrease the amount of intracellular β-catenin. Finally, the level of intracellular β-catenin was also decreased by blocking the mitochondrial electron transport chain with rotenone. These results suggest that a mitochondrial dysfunction due to metabolic inhibition negatively regulates the Wnt/β-catenin pathway.
To screen cell-permeable small molecule inhibitors of the Wnt/b-catenin pathway, I used two reporter cell lines: HEK293-TOPFlash cells, which were stably transfected with human Frizzled-1 (hFz-1) expression and a synthetic β-catenin/Tcf-dependent luciferase reporter plasmids, to assay β-catenin response transcription (CRT); and HEK293-RL cells, which stably harbored hFz-1 expression and CMVRenilla luciferase plasmids, as a control. After adding the Wnt3a-CM and each compound to these reporter cells, the firefly luciferase (FL) and Renilla luciferase (RL) activities were measured using a microplate reader. The FL activity was normalized to the RL activity in each well to evaluate the specific effects of the screened compounds. As shown in Figure 1 (a) and (b), antimycin A was found to inhibit the Wnt/β-catenin pathway. Treatment of HEK293-TOPFlash cells with increasing amounts of amtimycin A caused a concentration-dependent decrease in CRT that had been stimulated by Wnt3a-CM without affecting the activity of FOPFlash, a negative control reporter with mutated β-catenin/Tcf binding elements; a concentration of 20 μM antimycin A induced the near-complete inhibition of CRT relative to the control treatment ( Fig. 1(c) ). In addition, antimycin A consistently suppressed the Wnt3a-induced secreted alkaline phosphatase (SEAP) activity in the HEK293-TOPSEAP cells, which stably contained a β-catenin/Tcfdependent SEAP reporter and hFz-1 plasmid ( Fig. 1(d) ). Overall, these results suggest that antimycin A is a specific antagonist of the Wnt/β-catenin pathway.
The Wnt/β-catenin pathway is controlled mainly by the intracellular β-catenin level.
4 Therefore, I examined whether antimycin A affects the cytosolic β-catenin level by Western blot analysis with the anti-β-catenin antibody. Incubation of HEK293-TOPFlash cells with antimycin A resulted in a decrease in the cytosolic β-catenin level that had been accumulated by Wnt3a-CM, which is consistent with its effect on CRT ( Fig. 2(a) ). In contrast, the mRNA level of β-catenin was unchanged by antimycin A regardless of the concentration ( Fig. 2(b) ), indicating that antimycin A suppresses the Wnt/β-catenin pathway by decreasing the β-catenin protein level.
Antimycin A causes a mitochondrial dysfunction by inhibiting the mitochondrial electron transport system through its binding to complex III. 15 2-Methoxyantimycin A3, an inactive derivative of antimycin A that maintains Bcl-2/Bclx L binding activity but does not inhibit electron transport, 16 was used to determine if an antimicin A-induced mitochondrial dysfunction inhibits the Wnt/β-catenin pathway directly. When HEK293-TOPFlash cells were incubated with various concentrations of 2-methoxyantimycin A3, 2-methoxyantimycin A3 did not affect CRT at any of the concentrations tested ( Fig. 3(a) ). In parallel with this experiment, the effect of 2-methoxyantimycin A3 on the levels of cytosolic β-catenin in HEK293-TOPFlash cells was examined by Western blot analysis. Consistent with the results from reporter assays, the addition of 2-methoxyantimycin A3 to the HEK293-TOPFlash cells did not down-regulate the intracellular β-catenin levels ( Fig. 3(b) ). These results suggest that the Wnt/β-catenin pathway is specifically suppressed by a mitochondrial dysfunction induced by the inhibition of the electron transport chain.
The effect of rotenone, an inhibitor of complex I in mitochondrial electron transport chain, 17 on the Wnt/β-catenin pathway was examined to confirm that the mitochondrial dysfunction induced by metabolic inhibition negatively regulates the Wnt/β-catenin pathway. As expected, treatment of HEK293-TOPFlash cells with various amounts of rotenone resulted in a significant decrease in CRT, which had been activated by Wnt3a-CM, in a concentration-dependent manner (Fig. 4(a) ). Consistent with this result, rotenone de- creased the amount of cytosolic β-catenin in HEK293-TOPFlash cells (Fig. 4(b) ), suggesting that rotenone also inhibits the Wnt/β-catenin pathway by down-regulating the intracellular β-catenin level.
Several studies suggested the possible interaction between Wnt signaling and the mitochondrial physiology. A recent study reported that Wnt signaling activates mitochondrial biogenesis and the generation of reactive oxygen species (ROS). 18 In addition, treatment with LiCl, an agonist of the Wnt/β-catenin pathway, increases mitochondrial biogenesis. 19 Moreover, stimulation of the Wnt/β-catenin pathway inhibits mitochondria-mediated apoptosis in colon cancer cells. 20 Nevertheless, the effects of a change in the mitochondrial function on the Wnt/β-catenin pathway have not been studied. In the present study, a screen of the chemical library, consisting of bioactive compounds, produced antimycin A, an inducer of mitochondrial dysfunction, which specifically suppressed CRT stimulated by Wnt3a-CM. In contrast, 2-methoxyantimycin A3, which is unable to inhibit the mitochondrial electron transport chain, did not affect the Wnt/β-catenin pathway. Moreover, rotenone, a complex I inhibitor, significantly down-regulated Wnt3a-CM-induced CRT, suggesting that metabolic inhibitor-induced mitochondrial dysfunction causes the inhibition of the Wnt/β-catenin pathway.
The level of intracellular β-catenin is regulated by GSK-3β-dependent and -independent pathways. Several small molecules that down-regulate the β-catenin level through GSK-3β-independent pathway have been identified by highthroughput screening. We previously reported that hexachlorophene induced β-catenin degradation by up-regulating the expression of Siah-1, which interacts with the carboxyl terminus of APC and promotes the ubiquitination of β-catenin, in HCT116 and LS174T colon cancer cells containing a β-catenin mutation at the CK1/GSK-3β phnosphorylation sites. 21 In addition, galangin, a naturally occurring bioflavonoid, reduces the intracellular β-catenin level by an APC/Axin/GSK-3β-independent mechanism in CRT-positive cancer cells. 22 In the present study, antimycin A was unable to down-regulate the intracellular β-catenin protein level when the GSK-3β activity was blocked by pharmacological inhibitors, LiCl and 6-bromoindirubin-3'-oxim (BIO), suggesting that a mitochondrial dysfunction causes a decrease in Notes the amount of β-catenin protein through a mechanism dependent of GSK-3β. Future studies will further investigate the mechanism of metabolic inhibitors-mediated β-catenin down-regulation.
In summary, the mitochondrial dysfunction-induced suppression of the Wnt/β-catenin pathway was identified by cell-based small molecule screening. Antimycin A and rotenone, which are inhibitors of the mitochondrial electron transport chain, inhibited the Wnt/β-catenin pathway by reducing the intracellular β-catenin protein level via a mechanism dependent on GSK-3β.
Experimental Section
Cell Cultures. HEK293 and Wnt3a-secreting L cells were obtained from the American Type Culture Collection and maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 120 µg/mL penicillin, and 200 µg/mL streptomycin. Wnt3a-conditioned medium (Wnt3a-CM) was prepared as described previously.
21 HEK293-TOPFlash, HEK293-FOPFlash, and HEK293-TOPSEAP cells were established as previously described. 21, 23 The HEL293-RL cell line was established by selecting HEK293 cells co-transfected with the plasmid expressing hFz-1 and pRL-CMV vector (Promega) using media containing G418 (1 mg/mL).
Chemicals, Transfection and Reporter Assays. Antimycin A, rotenone, and BIO were purchased from Sigma-Aldrich. 2-methoxyantimycine A3 were obtained from Enzo Life Sciences. The transfections were performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Luciferase assays were performed using a Dual luciferase assay kit (Promega) and a secreted alkaline phosphatase assay was carried out using Phospha-Light TM Assay kit (Applied Biosystems).
Screening for Small-Molecule Inhibitors of the Wnt/β-Catenin Pathway. The HEK293-TOPFlash and HEK293-RL cells were mixed and plated into 96-well plates at 15,000 cells per well in duplicate. 24 h later, Wnt3a-CM and the compounds (Genesis Plus Collection, MicroSource Discoverty Inc.) were added to the wells at a final concentration of 20 μM. After 15 h, the plates were assayed for the firefly luciferase and Renilla luciferase activities.
Western Blot and Antibodies. The cytosolic fraction was prepared using a methodology reported elsewhere. 24 The proteins were separated using 4-12% gradient SDS-PAGE (Invitrogen) and transferred to PVDF membranes (Amersham Bioscience) by wet blotting. The membranes were blocked with 5% nonfat milk in TBS-T (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% tween 20) and probed with the primary antibodies (1:1000). The membranes were then incubated with horseradish peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG (Santa Cruz Biotechnology, 1:2500) and visualized by ECL chemiluminescence (Santa Cruz Biotechnology). The antibody against β-catenin was purchased from BD Transduction Laboratories. β-Actin antibody was obtained from Cell Signaling Technology.
RNA Extraction and Semiquantitative RT-PCR. The total RNA was isolated with TRIzol reagent (Invitrogen) in accordance with the manufacturer's instructions, cDNA synthesis, reverse transcription, and PCR were performed as described previously. 21 The amplified DNA was separated on 1.5% agarose gels and stained with ethidium bromide.
